Genetically modified tumour vaccines producing IL-12 augment chemotherapy of HPV16-associated tumours with gemcitabine

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68378050%3A_____%2F11%3A00365072" target="_blank" >RIV/68378050:_____/11:00365072 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.3892/or.2011.1221" target="_blank" >http://dx.doi.org/10.3892/or.2011.1221</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3892/or.2011.1221" target="_blank" >10.3892/or.2011.1221</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Genetically modified tumour vaccines producing IL-12 augment chemotherapy of HPV16-associated tumours with gemcitabine

Popis výsledku v původním jazyce

Genetically modified tumour cells producing cytokines such as IL-12 are potent activators of antitumour immune responses and a promising therapeutic modality when combined with chemotherapy. We examined whether IL-12-producing cellular vaccines can augment chemotherapy of HPV 16-associated murine tumours with cytostatic agent gemcitabine (GEM). Peritumoral administration of IL-12-producing tumour vaccines enhanced the effect of cytoreductive therapy with GEM in non-metastasizing murine carcinoma TC-1 and in metastasizing murine carcinoma MK16. Lung metastases in mice were substantially decreased. In surgical minimal residual tumour disease IL-12-producing tumour vaccine and GEM after MK16 tumour surgery also reduced tumour recurrences and metastases. Tumour inhibitory effects of GEM plus IL-12 were associated with high production of interferon-? by splenocytes. IL-12-producing vaccine can thus enhance the effect of GEM chemotherapy in some HPV16-associated murine tumour models.

Název v anglickém jazyce

Genetically modified tumour vaccines producing IL-12 augment chemotherapy of HPV16-associated tumours with gemcitabine

Popis výsledku anglicky

Genetically modified tumour cells producing cytokines such as IL-12 are potent activators of antitumour immune responses and a promising therapeutic modality when combined with chemotherapy. We examined whether IL-12-producing cellular vaccines can augment chemotherapy of HPV 16-associated murine tumours with cytostatic agent gemcitabine (GEM). Peritumoral administration of IL-12-producing tumour vaccines enhanced the effect of cytoreductive therapy with GEM in non-metastasizing murine carcinoma TC-1 and in metastasizing murine carcinoma MK16. Lung metastases in mice were substantially decreased. In surgical minimal residual tumour disease IL-12-producing tumour vaccine and GEM after MK16 tumour surgery also reduced tumour recurrences and metastases. Tumour inhibitory effects of GEM plus IL-12 were associated with high production of interferon-? by splenocytes. IL-12-producing vaccine can thus enhance the effect of GEM chemotherapy in some HPV16-associated murine tumour models.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

EB - Genetika a molekulární biologie

OECD FORD obor

—

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2011

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Oncology Reports

ISSN

1021-335X

e-ISSN

—

Svazek periodika

25

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

GR - Řecká republika

Počet stran výsledku

7

Strana od-do

1683-1689

Kód UT WoS článku

000290649600027

EID výsledku v databázi Scopus

—